Furthermore, a recently reported AR-V7 specific target, SREBF1 [22], was remarkably down-regulated when ABCC5-ablation, and even lower when combined with enzalutamide-treatment, which indicating that ABCC5 may regulate drug resistance of PCa cells via AR-V7. This evidence concerns the gene ABCC5 and posterior cortical atrophy.